Next-generation yellow fever vaccine shows comparable efficacy to standard vaccine
1. A next-generation live-attenuated yellow fever vaccine (vYF) demonstrated noninferior immunogenicity in contrast to the standard vaccine, with almost common seroconversion by one month after vaccination. 2. Safety profiles had been related between teams, with no vaccine-related critical adversarial occasions noticed over one 12 months of follow-up. Evidence Rating Level: 1 (Excellent) Study Rundown: Yellow…
